Shock Wave and Core Exercises for Postpartum Sacroiliac Pain

Sponsor
Cairo University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06124365
Collaborator
(none)
40
2
2.5

Study Details

Study Description

Brief Summary

Despite the high popularity and novelty of shock wave therapy (SWT), it is surprising that just one study has examined the effect of SWT on patients with SIJD and their functional ability following treatment by using subjective assessment tools like numeric rating scale (NRS) and limited by its small sample size and lack of long-term follow-up. Therefore, the present study is expected to contribute to the body of knowledge by exploring the effect of adding SWT to core stability exercises in the management of postpartum sacroiliac joint pain.

Condition or Disease Intervention/Treatment Phase
  • Other: Shock wave therapy and core stability exercises
  • Other: core stability exercises only
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effect of Adding Shock Wave Therapy to Core Stability Exercises in Treatment of Postpartum Sacroiliac Joint Pain: A Single-blinded, Randomized Controlled Trial.
Anticipated Study Start Date :
Nov 10, 2023
Anticipated Primary Completion Date :
Jan 15, 2024
Anticipated Study Completion Date :
Jan 25, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: study group

Other: Shock wave therapy and core stability exercises
20 post-partum women with SIJP will be treated by ESWT once weekly combined with core stability exercises 3 times per week for 6 weeks.

Active Comparator: Control group

Other: core stability exercises only
20 post-partum women with SIJP will be treated by core stability exercises 3 times per week for 6 weeks.

Outcome Measures

Primary Outcome Measures

  1. Sacroiliac joint pain intensity [change from base line at 6 weeks.]

    Sacroiliac joint pain intensity will be measured by visual analogue scale

  2. pain pressure threshold [change from base line at 6 weeks.]

    pain pressure threshold will be measured by pressure algometer

  3. functional disability [change from base line at 6 weeks]

    functional disability will be measured by Oswestry disability index

Secondary Outcome Measures

  1. quality of life [change from base line at 6 weeks.]

    quality of life will be measured by the standard quality of life assessment tool which is known as the short-form SF 36 tool

Eligibility Criteria

Criteria

Ages Eligible for Study:
25 Years to 35 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • post-partum women diagnosed with SIJP with limitation of its movement referred from the orthopedist.

  • Age is between 25-35 years old.

  • Their body mass index will be ranged from 25-35 kg/m2.

Exclusion Criteria:
Patients who have one of the following criteria will be excluded from the study:
  • Previous spinal surgery.

  • Medical diagnosis other than SIJ dysfunction.

  • Patients who had any other spine disorders.

  • Patients who had leg length discrepancies.

  • Patients with congenital postural deformities.

  • Patients with spinal cord injury or acute or unstable neurological signs.

  • Patients with cauda equina symptoms related to the spine including changes in bowel or bladder control and perineal sensation.

  • Patients with lumber intervertebral disc, spondylosis, lumbar canal stenosis and spondylolysthesis.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Cairo University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Marwa Shafiek Mustafa Saleh, assistance professor doctor, Cairo University
ClinicalTrials.gov Identifier:
NCT06124365
Other Study ID Numbers:
  • Postpartum sacroiliac pain
First Posted:
Nov 9, 2023
Last Update Posted:
Nov 9, 2023
Last Verified:
Nov 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 9, 2023